Trial Profile
Phase II Trial of Molecularly Determined Treatment of Children and Young Adults With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib (Primary) ; Temozolomide (Primary)
- Indications Diffuse intrinsic pontine glioma; Glioma
- Focus Therapeutic Use
- 13 Aug 2019 Status changed from completed to discontinued.
- 17 Jul 2018 Status changed from active, no longer recruiting to completed.
- 25 Jul 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2018.